Melatonina
Anno: 1994
-
Riferimento:Oncology. 1994 May-Jun;51(3):288-95.Azione della melatonina:Nocturnal melatonin levels were significantly reduced by exposure to this weak alternating MF.Target:Magnetic fields (MFs)
-
Riferimento:J Pineal Res. 1994 May;16(4):215-22.Azione della melatonina:Antitumor effect through a cell-cycle-specific mechanism by delaying the entry of cells into mitosis.Target:Smaller cell and nuclear sizes
-
Riferimento:Life Sci. 1994;54(21):1531-43. Review.Azione della melatonina:Reduction of circulating levels of melatonin.Target:50/60-Hz MF
-
Titolo: Melatonin concentrations in pineal organ culture are suppressed by sera from tumor-bearing miceRiferimento:J Pineal Res. 1994 Aug;17(1):17-9.Azione della melatonina:Melatonin rhythmicity is suppressed in cancer patients.Target:Plasma borne tumor-associated factor (TAMF).
-
Riferimento:J Natl Cancer Inst. 1994 Jun 15;86(12):921-5.Azione della melatonina:Exposure to extremely low-frequency electromagnetic fields reduces the pineal gland's nocturnal production of the hormone melatonin.Target:Electric or magnetic fields.
Anno: 1995
-
Riferimento:Med Hypotheses. 1995 Jan;44(1):39-46.Azione della melatonina:Mindfulness meditation is associated with increased physiological levels of melatonin.Target:Effect of meditation on 6-sulphatoxymelatonin
-
Riferimento:Carcinogenesis. 1995 Dec;16(12):2945-9.Azione della melatonina:Oncostatic action of melatonin[10(-10) M]is exerted through modulation of the levels of gap junctional intercellular communication. Also, the data indicate that ELF-MF could counteract the melatonin-induced enhancement of junctional transfer.Target:Extremely low frequency (ELF magnetic fields(MF)
-
Titolo: Melatoni blocks the stimulatory effects of prolactin on human breast cancer cell growth in cultureRiferimento:Br J Cancer. 1995 Dec;72(6):1435-40.Azione della melatonina:Mlt interrupts the PRL receptor (PRLR)-mediated growth signal in HBC and suggest that the oncostatic activity of Mlt may also be linked with an antagonism of PRL's actions.Target:Monoclonal antibodies (Mabs) against PRLR
-
Riferimento:Oncol Rep. 1995 Nov;2(6):1063-8.Azione della melatonina:Induce objective tumor regressions in most advanced solid tumor histotypes by low-dose IL-2 plus MLT (orally at 40 mg/day).Target:Interleukin-2 (IL.2)
-
Riferimento:Anticancer Res. 1995 Nov-Dec;15(6B):2633-7.Azione della melatonina:Patients with multiple myeloma showed significantly higher mean melatonin serum levels, increased secretion might be considered as a compensatory mechanism of regulating neoplastic growth.Target:Antineoplastic activity.